Clinical Application of Imaging Navigation Technology in the Treatment of Pulmonary Tuberculosis

Objective: To observe the clinical effect of targeted perfusion with DSA-guided bronchoscope in the treatment of multidrug-resistant pulmonary tuberculosis (MDR-TB). Methods: A total of 188 patients with multidrug-resistant pulmonary tuberculosis (MDR-TB) who were hospitalized for treatment between September 2023 and September 2024 were included. After random division, 94 cases were included in the control group and received systemic anti-tuberculosis chemotherapy; 94 patients were included in the treatment group. Based on digital subtraction angiography (DSA), targeted drugs were injected into the bronchoscope cavity to complete anti-tuberculosis treatment. The sputum and imaging changes were observed in both groups. Results: The sputum negative rate of the treatment group was significantly higher than that of the control group (86.2%; 70.2%) (u = 2.74, P < 0.01). The absorption rate of CT image lesion (significant absorption + partial absorption) was significantly higher than that of control group (83.0%; 50%) (u = 2.45, P < 0.05). The closure rate of chest CT cavity was significantly higher than that of control group (74.2%; 39.1%) (u = 2.20, P < 0.05). The improvement rate of clinical symptoms in the treatment group was statistically higher than that in the control group. There was no significant difference in the incidence of adverse reactions between the two groups (x = 0.434, P > 0.05). Conclusion: Based on inclusion in 20DSA, infusion of targeted drugs into bronchoscopy can significantly improve disease efficacy, with mild adverse reactions that patients can tolerate, and is worthy of promotion and application.